Drug Substance Siegfried Holds Groundbreaking Ceremony for New Global R&D Center

Source: Press release Ahlam Rais 1 min Reading Time

Related Vendors

Siegfried recently held a groundbreaking ceremony to develop a new global drug substance research and development center in Evionnaz, Switzerland. The firm has plans to invest 28 million dollars for the project.

In the new building more than 100 highly qualified specialists will work closely with customers to bring their valuable innovations to industrial scale. (Source:  Siegfried)
In the new building more than 100 highly qualified specialists will work closely with customers to bring their valuable innovations to industrial scale.
(Source: Siegfried)

Zofingen/Switzerland – Siegfried, a global leader in contract development and manufacturing (CDMO), recently broke ground on its new global drug substance research and development center in Evionnaz, Switzerland. The new center will start operations in 2024 and, together with the R&D center in Zofingen, will significantly increase Siegfried's R&D capacities and thus drive future growth.

In the new building, in which Siegfried will invest up to 28 million dollars, more than 100 highly qualified specialists will work closely with customers to bring their valuable innovations to industrial scale. The R&D center will house advanced chemical and analytical facilities, state-of-the-art laboratories and will provide chemical process research and analytical development services for the entire Drug Substances network. With this project, Siegfried is further expanding its site in Evionnaz, an important pillar within the global Drug Substances network.

Wolfgang Wienand, Siegfried CEO: “The new R&D center in Evionnaz strengthens our global network and underlines our commitment to offer our customers the most modern research and development services. It is a key milestone in our successful growth strategy and another significant step on our journey to becoming the leading CDMO in our space."

(ID:49431946)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent